Table 3.
Antimycobacterial activity data of target compounds (5a–5n) by microdilution method
| Compounds | MIC (lMC) MTB H37Rv Clinical isolate of MTB | |||
|---|---|---|---|---|
| 15th day | 21 days | 15th day | 21 days | |
| 5a | NA | NA | NA | NA |
| 5b | NA | NA | NA | NA |
| 5c | NA | NA | NA | NA |
| 5d | 8 | 8 | 8 | 8 |
| 5e | 8 | 8 | 16 | 16 |
| 5f | 16 | 16 | 16 | 16 |
| 5g | 31 | 31 | NA | NA |
| 5h | NA | NA | NA | NA |
| 5i | 8 | 8 | 8 | 8 |
| 5j | NA | NA | NA | NA |
| 5k | NA | NA | NA | NA |
| 5l | 16 | 16 | NA | NA |
| 5m | NA | NA | NA | NA |
| 5n | NA | NA | NA | NA |
| INH | 0.28 | 0.28 | 8 | 8 |
| R | 0.09 | 0.09 | 2 | 2 |
| S | 2 | 2 | 2 | 2 |
| E | 4 | 4 | 4 | 4 |
Controles used were first line drugs INH-isoniazid
S Streptomycin, E Ethambutol, R Rifampicin, NA compound was not active TB isolates